文献リスト

1) Lok AS. Navigating the maze of hepatitis B treatments. Gastroenterology. 2007; 132: 1586-94

2) 西口修平. IFN治療. In: 矢野右人, 林 紀夫, 沖田 極, 編. コンセンサス肝疾患2002. 第1版. 東京: 日本メディカルセンター; 2002. p. 71-7

3) Wong DK, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med. 1993; 119: 312-23

4) Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy？ A statistical analysis of predictive factors. Hepatology. 1989; 10: 761-3

5) Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. New Engl J Med. 1990; 323: 295-301

6) Lok AS, WuPC, Lai CL, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology. 1992; 102: 2091-7

7) Ikeda K, Saitoh S, Suzuki Y, et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer. 1998; 82: 827-35

8) Lok AS, Chung HT, Liu VW, et al. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology. 1993; 105: 1833-8

9) Lin SM, Sheen IS, Chien RN, et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 1999; 29: 971-5

10) Kao JH, Wu NH, Chen PJ, et al. Hepatitis B genotypes and the response to interferon therapy. J Hepatol. 2000; 33: 998-1002

11) Wai CT, Chu CJ, Hussain M, et al. HBV genotype B is associated with better response to interferon therapy in HBeAg(＋) chronic hepatitis than genotype C. Hepatology. 2002; 36: 1425-30

12) Erhardt A, Reineke U, Blondin D, et al. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology. 2000; 31: 716-25

13) Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000—summary of a workshop. Gastroenterology. 2001; 120: 1828-53

14) Lampertico P, Del Ninno E, Manzin A, et al. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology. 1997; 26: 1621-5

15) Fattovich G, Farci P, Rugge M, et al. A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology. 1992; 15: 584-9

16) Hadziyannis S, Bramou T, Makris A, et al. Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. J Hepatol. 1990; 11: S133-6

17) Pastore G, Santantonio T, Milella M, et al. Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon. J Hepatol. 1992; 14: 221-5

18) Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol. 2001; 34: 306-13

19) Lampertico P, Del Ninno E, Manzin A, et al. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology. 1997; 26: 1621-5

20) Lampertico P, Del Ninno E, Vigano M, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology. 2003; 37: 756-63

21) Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005; 352: 2682-95

22) Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004; 351: 1206-17

23) Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial. Lancet. 2005; 365: 123-9

24) Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004; 351: 1206-17

25) Bonino F, Marcellin P, Lau GKK, et al. for the Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Predicting response to peginterferon-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut. 2007; 56: 699-705

26) Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. New Engl J Med. 1999; 341: 1256-63

27) Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998; 339: 61-8

28) Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut. 2000; 46: 562-8

29) Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology. 2000; 119: 172-80

30) Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology. 2001; 33: 1527-32

31) Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol. 2004; 19: 1276-82

32) Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003; 125: 1714-22

33) Song BC, Suh DJ, Lee HC, et al. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology. 2000; 32: 803-6

34) Lee KM, Cho SW, Kim SW, et al. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat. 2002; 9: 208-12

35) Ryu SH, Chung YH, Choi MH, et al. Long-term additional lamivudine therapy enhances durability of lamivudine- induced HBeAg loss: a prospective study. J Hepatol. 2003; 39: 614-9

36) Lee HC, Suh DJ, Ryu SH, et al. Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion. Gut. 2003; 52: 1779-83

37) Chien RN, Yeh CT, Tsai SL, et al. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology. 2003; 38: 1267-73

38) Asahina Y, Izumi N, Uchihara M, et al. Core promoter/pre-core mutations are associated with lamivudine-induced HBeAg loss in chronic hepatitis B with genotype C. J Hepatol. 2003; 39: 1063-9

39) Lok AS, Hussain M, Cursano C, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology. 2000; 32: 1145-53

40) Hadziyannis SJ, Papatheodoridis GV, Dimou E, et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2000; 32: 847-51

41) Rizzetto M, Volpes R, Smedile A. Response of pre-core mutant chronic hepatitis B infection to lamivudine. J Med Virol. 2000; 61: 398-402

42) Papatheodoridis GV, Dimou E, Laras A, et al. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology. 2002; 36: 219-26

43) Santantonio T, Mazzola M, Iacovazzi T, et al. Long-term follow-up of patients with anti-HBe/HBV DNApositive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol. 2000; 32: 300-6

44) Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology. 2005; 42: 121-9

45) Yuen MF, Sablon E, Hui CK, et al. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology. 2001; 34: 785-91

46) Matsumoto A, Tanaka E, Minami M, et al. Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy. Hepatol Res. 2007; 37: 661-6

47) Hatakeyama T, Noguchi C, Hiraga N, et al. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine. Hepatology. 2007; 45: 1179-86

48) Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003; 348: 808-16

49) Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003; 348: 800-7

50) Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg negative chronic hepatitis B. N Engl J Med. 2005; 352: 2673-81

51) Peters MG, Hann H, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2004; 126: 91-101

52) Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology. 2003; 125: 292-7

53) Villeneuve JP, Durantel D, Durantel S, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol. 2003; 39: 1085-9

54) Locarnini S, Qi X, Arterburn S, et al. Incidence and predictors of emergence of Adefovir resistant HBV during four years of Adefovir Dipivoxil (ADV) Therapy for patients with chronic hepatitis B (CHB). J Hepatol. 2005; 42: 17

55) Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol. 2006; 44: 283-90

56) Lee YS, Suh DJ, Lim YS, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology. 2006; 43: 1385-91

57) Snow A, Thibault V, Qi X, et al. Combination of Adefovir Dipivoxil (ADV) and Lamivudine (LAM) prevented emergence of ADV resistance mutations in chronic hepatitis B (CHB) patients with LAM-resistant HBV. Gastroenterology. 2005; 128: M945

58) Yatsuji H, Suzuki F, Sezaki H, et al. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J Hepatol. 2008; 48: 923-31

59) Ono SK, Kato N, Shiratori Y, et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest. 2001; 107: 449-55

60) Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006; 354: 1001-10

61) Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006; 354: 1011-20

62) Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology. 2007; 133: 1437-44

63) Chang TT, Gish RG, Hadziyannis SJ, et al. A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology. 2005; 129: 1198-209

64) Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology. 2006; 130: 2039-49

65) Suzuki F, Toyoda J, Katano Y, et al. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: Randomized controlled trial in Japanese patients. J Gastroenterol Hepatol. 2008. in press

66) Villeneuve JP, Durantel D, Durantel S, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol. 2003; 39: 1085-9

67) Colonno R, Rose R, Baldick C, et al. Resistance after two years of entecavir treatment in nucleoside-naive patients is rare. Hepatology. 2006; 45: 1656-65

68) Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology. 2006; 44: 1656-65

69) Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother. 2004; 48: 3498-507

70) Baldick CJ, Tenney DJ, Mazzucco CE, et al. Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance. Hepatology. 2008; 47: 1473-82

71) Yatsuji H, Hiraga N, Mori N, et al. Successful treatment of an entecavir-resistant hepatitis B virus variant. J Med Virol. 2007; 79: 1811-7

72) Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005; 129: 528-36

73) Lai CL, Leung NW, Teo EK, et al. Phase Iib extended-treatment trial of telbivudine (LdT) vs lamivudine vs combination treatment in hepatitis B patients: two year results. Gastroenterology. 2005; 128: A692

74) Lai CL, Gane E, Liaw YF, et al. Telbivudine (LDT) vs. lamivudine for chronic hepatitis B: First - year results from the international phase III globe trial. Hepatology. 2005; 42(Suppl): 748A

75) Lai CL, Gane E, Chao-Wei H, et al. Two-year results from the Globe Trial in patients with hepatitis B: Greater clinical and antiviral efficacy for telbivudine (LDT) vs. lamivudine. Hepatology. 2006; 44(Suppl): 222A

76) Lai CL, Gane E, Liaw Y, et al. The Globe Study Group. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007; 357: 2576-88

77) Chan HLY, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir. a randomized trial. Ann Int Med. 2007; 147: 745-54

78) Lim SG, Ng TM, Kung N, et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med. 2006; 166: 49-56

79) Ristig MB, Crippin J, Aberg JA, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis. 2002; 186: 1844-7

80) Peters MG, Anderson J, Lynch P, et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology. 2006; 44: 1110-6

81) Benhamou Y, Fleury H, Trimoulet P, et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology. 2006; 43: 548-55

82) Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapynaive and-experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis. 2004; 189: 1185-92

83) Kuo A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol. 2004; 2: 266-72

84) van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology. 2004; 40: 1421-5

85) Yoo BC, Kim H, Lee KS, et al. A 24-week clevudine monotherapy produced profound on-treatment viral suppression as as sustained viral suppression and normalization of aminotransferase levels for 24 weeks off-treatment in HBEAg(/)chronic hepatitis B patients. Hepatology. 2005; 42(Suppl): 270A

86) Yoo BC, Koh KC, Chung YH, et al. Clevudine is highly efficacious in HBEAg positive chronic hepatits B patients with a sustained antiviral effect after cessation of therapy. Hepatology. 2005; 42(Suppl): 268A

87) Chan HL, Leung NW, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med. 2005; 142: 240-50

88) Schiff ER, Dienstag JL, Karayalcin S, et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol. 2003; 38: 818-26

89) Sung JJY LJ, Zeuzem S, Chow WC, et al. A randomized double-blind phase II study of lamivudine compared to lamivudine plus adefovir dipivoxil for treatment naive patients with chronic hepatitis B: week 52 analysis. J Hepatol. 2003; 38(Suppl 2): 25-6

90) A Phase II Study of Lamivudine Compared to Lamivudine Plus Adefovir Dipivoxil for Subjects With Chronic Hepatitis B. http://ctr.gsk.co.uk/Summary/lamivudine/II_NUC20912

91) Yim HJ, Hussain M, Liu Y, et al. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology. 2006; 44: 703-12

92) 熊田博光. 総括研究報告書 B型及びC型肝炎ウイルスの感染者に対する治療標準化に関する臨床的研究 厚生労働省科学研究費 肝炎等克服緊急対策研究事業(肝炎分野, 主任研究者 熊田博光). 平成19年度総括・分担研究者報告書 B型及びC型肝炎ウイルスの感染者に対する治療標準化に関する臨床的研究. 2008

93) Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007; 45: 507-39. Erratum in: Hepatology. 2007; 45: 1347

94) Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med. 1996; 334: 1422-7

95) Lau DT, Everhart J, Kleiner DE, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology. 1997; 113: 1660-7

96) van Zonneveld M, Honkoop P, Hansen BE, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology. 2004; 39: 804-10

97) Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol. 2001; 34: 306-13

98) Wong VW, Chan HL, Wong ML, et al. Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants. Aliment Pharmacol Ther. 2004; 19: 323-9

99) Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003; 124: 105-17

100) Liaw YF, Sung JJ, Chow WC, et al. Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004; 351: 1521-31

101) Matsumoto A, Tanaka E, Rokuhara A, et al. Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients. Hepatol Res. 2005; 32: 173-84

102) Di Martino V, Thevenot T, Colin J, et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology. 2002; 123: 1812-22

103) Hoff J, Bani-Sadr F, Gassin M, et al. Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a componet of anti-human immunodeficiency virus regimens. Clin Infect Dis. 2001; 32: 963-9

104) Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patitents. Hepatology. 2000; 31: 1030-1

105) Bani-Sadr F, Palmer P, Scieux C, et al. Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus. Clin Infect Dis. 2004; 39: 1062-4

106) Sheldon JA, Corral A, Rodes B, et al. Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir. AIDS. 2005; 19: 2036-8

107) Lin PF, Nowicka-Sans B, et al. Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. Antimicrob Agents Chemother. 2008; 52: 1759-67

108) McMahon M, Jilek B, Brennan T, et al. The anti-hepatitis B drug entecavir inhibits HIV-1 replication and selects HIV-1 variants resistant to antiretroviral drugs. Presented at the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, February 2007

109) Lok AS, Liang RH, Chiu EK, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991; 100: 182-8

110) Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000; 62: 299-307

111) Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006; 43: 209-20

112) Cheng AL, Hsiung CA, Su IJ, et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology. 2003; 37: 1320-8

113) Ostuni P, Botsios C, Punzi L, et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis. 2003; 62: 686-7

114) Esteve M, Saro C, Gonzalez-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut. 2004; 53: 1363-5

115) Lau GK, He ML, Fong DY, et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology. 2002; 36: 702-9

116) Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003; 125: 1742-9

117) Rossi G, Pelizzari A, Motta M, et al. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol. 2001; 115: 58-62

118) Chan TM, Fang GX, Tang CS, et al. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology. 2002; 36: 1246-52

119) Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008; 148: 519-28

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp